Low molecular weight heparin composition and uses thereof

一种低分子量肝素、重均分子量的技术，应用在含有效成分的医用配制品、有机活性成分、过敏性疾病等方向，能够解决不是常规试验或易于实施、昂贵等问题

Inactive Publication Date: 2012-10-10
MOMENTA PHARMA INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This test is very expensive (well in excess of $100.00) and is not routine or easy to perform because samples typically must be sent to an outside laboratory for analysis
Therefore, the use of LMWH has so far been mainly limited to prophylaxis rather than treatment of thrombosis, and the patient population for which LMWH can be administered is also limited: Pediatric patients, after RFI, urea, sarcosine, phosphorus, glomerular filtration rate (GFR) or blood and urine BUN (blood urea nitrogen level) tests Patients with abnormal renal function and interventional heart disease patient groups were excluded

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Low molecular weight heparin composition and uses thereof
  • Low molecular weight heparin composition and uses thereof
  • Low molecular weight heparin composition and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0460] The present invention is further illustrated by the following examples, which should not be construed as limiting the present invention. The contents of all references, patents and published patent applications cited in this application are hereby incorporated by reference.

Embodiment

[0462] Method of producing M118-REH

[0463] production process

[0464] figure 1A schematic flow chart for the production of M118-REH is shown. Briefly, in the first step of the protocol, commercially available unfractionated heparin USP (UFH) was serially precipitated using calcium acetate in ethanol in water (3:1 mass ratio calcium acetate / UFH) to extract the low molecular weight Fraction of UFH (also referred to as fraction of substantially fast moving components). The product isolated in Step 1 is referred to as Intermediate 1.

[0465] Step 2 involves digesting intermediate 1 with a modified heparanase III having a histidine to Amino acid residue substitution at position 225 of alanine (MO11). MO11 is cleaved by β-elimination between an N-acetylglucosamine residue and a subsulfated uronic acid to produce a Δ4,5 uronic acid group at the non-reducing end and N-acetylglucosamine at the reducing end chain. When the degradation was complete, the heating was stopped...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.

Description

[0001] This application claims U.S. Provisional Application No. 60 / 809,136, filed May 25, 2006, U.S. Provisional Application No. 60 / 849,578, filed October 4, 2006, and U.S. Provisional Application No. 60 / 849,578, filed October 5, 2006. Priority to Application Serial No. 60 / 849,628, the contents of which are incorporated herein by reference. Background technique [0002] Coagulation is a physiological pathway involved in maintaining normal hemostasis in mammals. In the event of a blood vessel injury, the coagulation pathway is activated to form a blood clot, preventing blood loss. Immediately after a blood vessel injury occurs, platelets begin to clump together at the injured site to form a physical blockage to stop blood loss. In addition, injured blood vessels reduce blood flow through the area through vasoconstriction, while fibrin begins to clump to form an insoluble network, or clot, that covers the ruptured area. [0003] When the coagulation pathway is in an imbalance ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C08B37/10A61K31/727
CPCC08B37/0078A61P11/00A61P11/06A61P17/02A61P19/00A61P19/02A61P19/04A61P19/10A61P25/28A61P31/04A61P35/00A61P35/04A61P37/06A61P37/08A61P43/00A61P7/02A61P9/00A61P9/02A61P9/04A61P9/10
Inventor 马利克·孙达拉姆加内什·文卡塔拉曼帕特丽夏·奥利弗姚一鸣扎伊纳布·西拉布海·马穆瓦拉伊恩·菲尔齐意伟扎卡里·施赖弗伊尚·卡皮拉努尔·西贝尔·居那伊达妮埃拉·贝卡蒂刘翠华科琳娜·鲍尔李颖
Owner MOMENTA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap